We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Amgen Sues FDA Over Exclusivity For Blockbuster Sensipar

Law360, New York (May 26, 2017, 7:01 PM EDT) -- The U.S. Food and Drug Administration improperly denied extra exclusivity for Amgen Inc.’s blockbuster calcium-control drug Sensipar despite years of exhaustive research conducted at the agency’s request, according to a new...
To view the full article, register now.




Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only


District Of Columbia

Nature of Suit

Other Statutory Actions


Subscribers Only

Date Filed

May 25, 2017

Law Firms


Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.